Novel approaches to immunotherapy for B-cell malignancies.
Novel approaches to immunotherapy for B-cell malignancies.
复制标题
DOI：
10.1007/s11912-004-0059-5
复制
发表时间：
2004-09-01
影响因子：
4.7
通讯作者：
Brentjens, Renier J
中科院分区：
文献类型：
--
作者：
Brentjens, Renier J
癌症的免疫疗法是指利用免疫系统靶向和根除宿主中的恶性细胞的一系列新型治疗干预措施。对肿瘤细胞如何逃避宿主免疫检测的理解的进展，加上改进的基因转导技术，使研究人员能够提出和测试针对B细胞恶性肿瘤的新型免疫疗法。因此，更多的免疫原性疫苗接种策略，能够引发免疫应答，否则免疫原性差的肿瘤抗原，正在早期临床试验中进行测试。此外，随着有效T细胞转导方法的发展，研究人员能够通过引入能够靶向肿瘤抗原的嵌合抗原受体来产生自体抗肿瘤T细胞应答。然而，这里提出的有希望的临床前和I期临床数据是否最终转化为B细胞恶性肿瘤患者的生存率提高仍然是未知的。
Immunotherapy for cancer refers to a wide array of novel therapeutic interventions that harness the immune system to target and eradicate malignant cells in the host. Advances in the understanding of how tumor cells evade host immune detection, coupled with improved gene transduction technologies, have enabled investigators to propose and test novel immune-based therapies for B-cell malignancies. As a result, more immunogenic vaccination strategies, able to elicit immune responses to otherwise poorly immunogenic tumor antigens, are being tested in early clinical trials. Furthermore, with the development of efficient T-cell transduction methodologies, investigators are able to generate autologous antitumor T-cell responses through the introduction of chimeric antigen receptors able to target tumor antigens. However, whether the promising preclinical and phase I clinical data presented here will ultimately translate into improved survival of patients with B-cell malignancies remains largely unknown.